Four publicly traded companies are facing class-action lawsuits. This is the investors’ alert.
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) deadline alert
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) is facing a class-action lawsuit. Bronstein, Gewirtz & Grossman, LLC is looking into the investigation part of this lawsuit filed against the publicly traded company. The class period stretches from March 17, 2020, to February 12, 2021. Thus, the deadline for this lawsuit is approaching, i.e., on August 9, 2021. The complaint focuses on the defendants giving misleading and false statements in context with DSUVIA’s efficacy and risks.
Aterian Inc (NASDAQ: ATER) class action for securities fraud
The class-action lawsuit period for this company is December 1, 2020 – May 3, 2021. The deadline for the lead plaintiff is arriving on July 12, 2021. The complaint has alleged Aterian Inc (NASDAQ: ATAR) for falsely touting the core business, functionalities of AIMEE (its artificial intelligence platform), and recent acquisitions. Hagens Berman is leading the investigation in the company. The partner in the investigation firm, Reed Kathrein, said that their focus relies on investors’ losses and proving that the company has misled its investors regarding the AIMEE platform and acquisitions.
Thornton Law Firm sends out investors alert for ContextLogic Inc (NASDAQ: WISH)
ContextLogic Inc. (NASDAQ: WISH) investors need to watch a class-action lawsuit filed against the company. The investigation firm is Thornton Law Firm. The firm calls for investors to seek protection. Those who’ve purchased the shares from December 16, 2020, to May 12, 2021, need to be careful for the same. The investors can seek an appointment with the law firm as the lead plaintiff.
Ocugen Inc (NASDAQ: OCGN) shareholder notification for approaching deadline
The investors who’ve bought Ocugen’s shares between February 2, 2021, and June 10, 2021, are notified by Levi & Korsinsky, LLP to stay alert for the class action lawsuit’s approaching deadline on August 17, 2021. The complaint includes the company’s failure in providing sufficient information to FDA for seeking Emergency Use Authorization for its drug, among other reasons.